Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 7/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 5/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102615 | 1.00 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1HDAC8HDAC6 | |
| SCHEMBL2161104 | 0.89 | ALDH1A1 (0.62) | SLC1A3SLC1A2SLC1A1MAPTMMP2 | |
| SCHEMBL1000596 | 0.89 | ALDH1A1 (0.62) | SLC1A3SLC1A2SLC1A1MAPTMMP2 | |
| SCHEMBL2161085 | 0.89 | ALDH1A1 (0.62) | SLC1A3SLC1A2SLC1A1MAPTMMP2 | |
| SCHEMBL2013525 | 0.89 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1MAPTMMP2 | |
| SCHEMBL8273982 | 0.86 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1HDAC8HDAC6 | |
| SCHEMBL7383649 | 0.85 | SLC1A3 (0.59) | SLC1A3SLC1A2SLC1A1MMP2CA12 | |
| SCHEMBL1491472 | 0.85 | SLC1A3 (0.59) | SLC1A3SLC1A2SLC1A1MAPTMMP2 | |
| SCHEMBL1491474 | 0.85 | SLC1A3 (0.59) | SLC1A3SLC1A2SLC1A1MAPTMMP2 | |
| SCHEMBL4538018 | 0.84 | HDAC8 (0.60) | SLC1A3SLC1A2SLC1A1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0212010-A1 | Color developers for pressure-sensitive or heat-sensitive recording papers | THE STANDARD REGISTER COMPANY (US) | 1987-03-04 | — | — | EP | claimed |
| US-4623391-A | COMPOUNDS HAVING ELECTRON-WITH DRAWING GROUPS WITHIN FIVE ATOMS OF A SULFANAMIDE | THE STANDARD REGISTER COMPANY (US) | 1986-11-18 | — | — | US | claimed |
| US-4531139-A | Color developers for pressure-sensitive or heat-sensitive recording papers | THE STANDARD REGISTER COMPANY (US) | 1985-07-23 | — | — | US | claimed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8372873-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2366704-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2364984-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1715885-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | Nastech Pharmaceutical Company Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080433-A2 | COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | SLC1A3 1847/4885SLC1A2 3159/4885SLC1A1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.